Pharmacological interventions for non-ulcer dyspepsia

Area of Science:

• Gastroenterology
• Clinical Pharmacology
• Evidence-Based Medicine

Background:

• Non-ulcer dyspepsia (NUD) is the most frequent cause of upper gastrointestinal symptoms.
• The pathophysiology of NUD remains poorly understood, leading to uncertainty in optimal treatment strategies.
• Significant healthcare expenditure, estimated at £450 million annually in the UK, is associated with NUD management.

Purpose of the Study:

• To systematically review and determine the efficacy of six drug classes in managing NUD symptoms.
• To assess the impact of these therapies on patients' quality of life.
• To compare the effectiveness of antacids, H2 antagonists, proton pump inhibitors, prokinetics, mucosal protectants, and antimuscarinics against placebo and each other.

Main Methods:

• Conducted comprehensive electronic searches of major databases (CCTR, MEDLINE, EMBASE, CINAHL, SIGLE) and relevant bibliographies.
• Included all randomized controlled trials (RCTs) comparing the six drug classes or placebo for NUD.
• Extracted data on individual/global dyspepsia symptom scores, quality of life, and adverse effects from eligible trials.

Main Results:

• Prokinetics (50% relative risk reduction) and H2RAs (30% RRR) demonstrated statistically significant improvements over placebo.
• Proton pump inhibitors and Bismuth salts showed marginal, non-significant superiority to placebo.
• Antacids and sucralfate did not provide statistically significant benefits compared to placebo; publication bias may affect prokinetic findings.

Conclusions:

• Anti-secretory therapies show potential efficacy in NUD, but further high-quality research is essential.
• Prokinetic therapy results require cautious interpretation due to potential publication bias.
• Future NUD treatments must be inexpensive, well-tolerated for long-term use, and supported by robust evidence.